Apraglutide

Apraglutide (FE 203799), a synthetic 33-amino-acid peptide and a long-acting GLP-2 analogue, enhances adaptation and linear intestinal growth in a neonatal piglet model of short bowel syndrome with total resection of the ileum[1].

Signaling Pathways >> Others >> Others

Research Areas >> Metabolic Disease

Apraglutide (FE 203799; 5 mg/kg/dose, subcutaneously, twice on days 0 and 4 postsurgery) treated piglets are healthy, have significant lower fecal fat and energy losses and exhibite intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth on day 7[1]. Animal Model: NewbornDuroc piglets, 2–5 days old and weighing between 2-2.6 kg[1]. Dosage: 5 mg/kg/dose. Administration: Subcutaneously, twice on days 0 and 4 postsurgery. Result: On day 7, treated piglets were healthy, had significant lower fecal fat and energy losses and exhibited intestinal lengthening, greater small-intestinal weight, longer villus height, and greater crypt depth.

[1]. Slim GM, et al. Novel Long-Acting GLP-2 Analogue, FE 203799 (Apraglutide), Enhances Adaptation and Linear Intestinal Growth in a Neonatal Piglet Model of Short Bowel Syndrome with Total Resection of the Ileum. JPEN J Parenter Enteral Nutr. 2019 Jan 6.